Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious procedure, conolidine modulates alternate molecular targets. A Science Developments study identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, wh